Slide 1: Sight Sciences
S Sight Sciences
Slide 2: Forward-Looking Statements
Forward-Looking Statements together with other 1933, and Section 1934, TheC provisions for Act of 1995. Fe historical fact, futi into ang tives; the Ci plans to invest in the C ability ability and ‘objectives; and the C. for “anticipate,” “expect,” “suggests,” “plan,” ‘believe," “intend,” “estimates
Slide 3: Mission Statement
sight Sciences MISSION STATEMENT Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care - empowering people to keep seeing. $13
Slide 4: A Glimpse Ahead
A Glimpse Ahead Innovation leader in two large, Near-term catalysts expected in Plan to return to double-digit growing, underserved markets market access revenue growth Strong balance sheet supports Strong gross margin and improving The transformation of chronic eye significant investments in R&D le
Slide 5: The Path to Early Intervention
The Path to Early Intervention A STRATEGIC ROADMAP TO TRANSFORM EYECARE Identify Identify patients who can benefit from intervention + 3.4MUS. patients diagnosed with Primary Open-Angle Glaucoma (POAG)! + 18MU.S. patients diagnosed with dry eye disease (DED)! Embrace Embrace intervention as a better
Slide 6: Glaucoma
Glaucoma
Slide 7: Glaucoma
Glaucoma Leading cause of irreversible blindness* Predominantly managed with daily eye drops (compliance often poor)' Normal Mild Moderate Severe Large + Underserved Markets — $6.0 billion addressable U.S. market? 3.4 million U.S. patients diagnosed with POAG$ 1 Newman-Casey PA, Robin AL, Blachley T
Slide 8: Primary Open-Angle Glaucoma (POAG)
Primary Open-Angle Glaucoma (POAG) The Conventional Outflow Pathway is an important focal point in treating POAG. POAG is similar to a clog in a kitchen sink: + The eye's natural drainage system is called the conventional outflow pathway. + Blockage of this system prevents aqueous fluid from drainin
Slide 9: Our Flagship Technology: OMNI
WOONVT9 TwOIDUNS OUR FLAGSHIP TECHNOLOGY Effective + Intuitive Intervention Sight Sciences Comprehensive treatment of diseased conventional outflow pathway I Leading Clinical Trial and Registry Results: > 2 6) 6) Cases ROMEO, GEMINI, AAO IRIS® Registry Performed! Offering a comprehensive interventio
Slide 10: Treatment of Canal and Collector Channels
Treatment of Canal and Collector Channels OMNI Comprehensively Treats the Conventional Outflow Pathway Minimally Invasive + Efficacious Acomprehensive procedure enabled by the OMNI Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance i
Slide 11: Broad FDA Indication
Broad FDA Indication ALLOWS FOR STANDALONE AND COMBINATION CATARACT UTILIZATION OMNI® Surgical System is the only Minimally Invasive Glaucoma Surgery (MIGS) device with an FDA indication that allows for: * Trabecular meshwork, Schiemm's canal, and collector channels Use in Standalone or combo catara
Slide 12: Consistent Efficacy of OMNI in Standalone and Combination Cataract Clinical Trials
Consistent Efficacy of OMNI in Standalone (SA) and Combination Cataract (CC) Clinical Trials COMBINATION CATARACT STANDALONE GEMINI ROMEO Elevated IOP CC ROMEO Elevated IOP SA TREY SA 25 (12 Months) (24 Months) (12 Months) (24 Months) Unmedicated Month 12 (n=113) Unmedicated Month 24 (n=17) Unmedica
Slide 13: OMNI Addresses All Six MIGS POAG Categories
OMNI Addresses All Six Minimally Invasive Glaucoma Surgery (MIGS) POAG Categories Allows surgeons to customize treatment AED STANDALONE MIGS S S B Opportunity! 85%! of POAG Eyes COMBINATION CATARACT MIGS <159%' of POAG Eyes MILD DISEASE MODERATE DISEASE ADVANCED DISEASE (40%)! (40%)! (20%)! ~$2B ~$2
Slide 14: Large and Unmet Clinical Need for Standalone MIGS
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone <15% of POAG eyes’, »90% of MIGS procedures? >85% of POAG eyes’, <10% of MIGS procedures? Established, growing market Large, underserved patient population Benefits from inherent lOP-lowering effect of cataract surgery
Slide 15: Standalone Market Development is Underway
Standalone Market Development is Underway Claims data indicate increasing standalone usage of codes associated with OMNI! OMNI technology meets enhanced efficacy and safety needs for standalone procedures + ROMEO + ROMEO two-year extension + TREY + Sole purpose of OR visit - degree and consistency o
Slide 16: Surgical Glaucoma Pipeline
Surgical Glaucoma Pipeline Developing Comprehensive Best-in-Class Portfolio CURRENT PRODUCTS Sight Sciences Sight Sciences IN THE PIPELINE Injection of Sustained Implantable Canalicular Suprachoroidal Release Pharmaceutical (Rx)* Scaffold (MIGS)* Implant (MIGS)* is under and isnot ‘The Company may s
Slide 17: Dry Eye Disease
Dry Eye Disease
Slide 18: Dry Eye Disease
Dry Eye Disease Linked to screen time, age (postmenopausal women, men 50+), systemic medication use Normal Mild Large + Underserved Markets $2.5 billion core addressable U.S. market?3 Predominantly managed with daily eye drops (compliance often poor)! Moderate Severe >11 million U.S. patients diagno
Slide 19: Overview: Tears and Meibomian Gland Disease (MGD)
Overview: Tears and Meibomian Gland Disease (MGD) TEAR FILM ANATOMY Tear film: j— Lacrimal gland + Tears consist of three layers + Outermost layer consists of oily substance called meibum = Coats and protects inner layers + Prevents premature evaporation MEIBOMIAN GLANDS + Healthy meibomian glands r
Slide 20: ~$2.5 Billion Core MGD Opportunity
~$2.5 Billion Core MGD Opportunity U.S. patients diagnosed with Dry Eye Disease (DED)! Up to 86% of DED is associated with poor tear quality due to meibomian gland disease (MGD) '? Targeted patients estimated to need 1.3 procedures per year® 17.9 million! 11.6 -15.4 million U.S. MGD patients! S2.2-$
Slide 21: Dry Eye Disease (DED): Large + Underserved Disease State
Dry Eye Disease (DED): Large + Underserved Disease State 95% Current market dominated by Rx and OTC eyedrops that do not address the underlying causes of MGD' 9./-7.9 million moderate to severe MGD DED patients"? ~50% of DED patients are moderate to severe’ (most likely to seek treatment + targeted
Slide 22: Our Technologies: TearCare
BAR ANO OUR TECHNOLOGIES Targeted + Intuitive Intervention TearCare . Sight Sciences Comprehensive treatment Leading Clinical Trial Results: > 5 5 Cases of diseased meibomian glands SAHARA, OLYMPIA Performed’ Offering a comprehensive intervention that drives leading clinical outcomes for evaporative
Slide 23: TearCare: Designed to Treat Meibomian Gland Disease (MGD)
TearCare: Designed to Treat Meibomian Gland Disease (MGD) TearCare is the only interventional, open-eye, dry eye technology designed to melt and comprehensively remove meibomian gland obstructions and restore gland functionality and healthy oil production. 01 Application 02 Therapy 03 Expression Thi
Slide 24: SAHARA RCT
SAHARA RCT PUBLICATION: CLINICAL OPHTHAMOLOGY DATE: DEC 2023 Randomized Controlled Trial comparing TearCare and Restasis® Superiority + Durability + TearCare vs Restasis? + Large Trial (N=345) + Randomized + Masked ‘Endpoints for SAHARA Wer Restasis at six months in our primary . tear break-up time.
Slide 25: SAHARA RCT: Results TearCare Superior to Restasis in Tear Breakup Time Improvement
SAHARA RCT: Results TearCare Superior to Restasis in Tear Breakup Time Improvement TearCare Results at 6 Months Absolute Change from Baseline at Each Time Point + Superior to Restasis' in tear break-up time HE Tearcare J Restasis + Non-inferior to Restasis in OSDI? + Significant improvements in all
Slide 26: TearCare Strategy: Targeted + Scalable Growth
TearCare Strategy: Targeted + Scalable Growth Actively Engaging in Pursuit of Equitable Market Access With the power of TearCare, we can: + Improve the lives of U.S. MGD patients + Scale commercial resources with market access wins + Target ~9,000 physicians identified as most likely to adopt MGD tr
Slide 27: What's Next
What's Next
Slide 28: Healthy Revenue Growth and Top-Tier Gross Margins
Healthy Revenue Growth and Top-Tier Gross Margins ANNUAL REVENUE & GROSS MARGIN % SGHT $27.6 DRY EYE S16 SURGICAL GLAUCOMA GROSS MARGIN % FY20 FY23 Y/Y Revenue +14% SGHT +13% Surgical Glaucoma +18% Dry Eye 85% ‘gen $6.7 FY21 FY22 FY23 FY23 Gross Margin % 85.3% SGHT 88.1% Surgical Glaucoma 54.8% Dry
Slide 29: Strategic Value Creation Initiatives
Strategic Value Creation Initiatives Represent Sustainable Growth Drivers Expand OMNI Utilization TearCare Access + Expansion + Certification of new OMNI surgeons + Pursue coverage and equitable reimbursement + Gain share in combination cataract segment + Generate additional clinical evidence + Cont
Slide 30: Why Now
Why Now’ Innovation leader in two large, Near-term catalysts expected in Plan to return to double-digit growing, underserved markets market access revenue growth Strong balance sheet supports Strong gross margin and improving The transformation of chronic eye significant investments in R&D leverage
Slide 31: Thank you!
Thank you! If you have any questions, please contact investor.relations@sightsciences.com © i ‘certain of